Loading...

Newron Pharmaceuticals S.p.A.

NP5.DE•XETRA
HealthcareMedical - Pharmaceuticals
$8.66
$-0.04(-0.46%)

Newron Pharmaceuticals S.p.A. (NP5.DE) Stock Overview

Explore Newron Pharmaceuticals S.p.A.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for NP5.DEStats details for NP5.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NP5.DEAnalyst Recommendations details for NP5.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

CEO

Mr. Stefan Weber

Employees

22

Headquarters

via Ludovico Ariosto 21, Bresso, MILANO

Founded

2019

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.